Cardiotoxicity
PRONOUNCE
CV events with degarelix (Firmagon, Ferring Pharmaceuticals) or leuprolide in patients with advanced prostate cancer and CVD.
CV safety of prostate cancer therapies ‘remains unresolved’: PRONOUNCE
In the PRONOUNCE trial, which aimed to compare the CV safety of androgen deprivation therapies for prostate cancer, there was no difference in major adverse CV events at 1 year among adults with prostate cancer and atherosclerotic CVD.
HF from cardiotoxic breast cancer therapies may confer better prognosis vs. other causes
Women who developed HF following cardiotoxic breast cancer treatment had fewer comorbidities and better overall 5-year prognosis compared with women who developed HF for other reasons, researchers reported.
VIDEO: Acalabrutinib equal to ibrutinib in PFS with less cardiotoxicity
In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed the study he presented at ASCO21 that showed progression-free survival rates were equal among patients with CML treated with acalabrutinib vs. ibrutinib.
VIDEO: Ponatinib dose-optimization beneficial for CML despite cardiac toxicity
In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed a pair of abstracts that looked at the use of ponatinib for Philadelphia chromosome positive ALL and resistant CML. One study looked at dose optimization of ponatinib for patients with CML, which indicated that starting treatment with a higher dose and then titrating down was effective.
Cardioprotective therapies fail to prevent LVEF decline in early breast cancer treatment
Neurohormonal blockade using candesartan and/or metoprolol for women undergoing treatment for early breast cancer was not significantly protective against minor long-term decline in left ventricular ejection fraction, a speaker reported.
Q&A: In breast, prostate cancer survivors, hormonal therapies may raise CV risk
Hormonal therapies for the treatment of breast and prostate cancers may improve survival among patients with cancer, but also may confer poor CV outcomes among survivors.
Inaugural symposium aims to foster ‘ongoing dialogue’ about cancer survivors’ unique needs
An estimated 17 million cancer survivors live in the United States.
FDA grants orphan drug designation to annamycin for soft tissue sarcoma
The FDA granted orphan drug designation to annamycin for the treatment of patients with soft tissue sarcoma, according to a manufacturer-issued press release.
IDH mutations linked to cardiotoxicity among adults with AML
Adults with acute myeloid leukemia with IDH mutations appeared to be at increased risk for coronary artery disease and exacerbated cardiotoxicity during treatment with anthracyclines, according to study results.